FEops has reported that data from a US-based comprehensive single centre experience where left atrial appendage occlusion (LAAO) procedures planned using the FEops HEARTguide demonstrated improved procedural efficiency.
The recent evaluation was conducted at St Bernard’s Medical Center and Arrhythmia Research Group.
The study involved 178 patients in the US and focused on assessing the safety, efficiency, and accuracy of predictive pre-planning based on cardiac CT-imaging with FEops HEARTguide for the Boston Scientific Watchman FLX and the Abbott Amplatzer Amulet.
A cloud-based predictive procedure planning tool, FEops HEARTguide utilises digital twin technology to offer preoperative insights to clinicians and medical device manufacturers. The data include how transcatheter structural heart devices interact with patient-specific anatomy.
The single-centre evaluation also showed that in 97% of cases, a successful LAAO device implantation was achieved with only one transseptal puncture.
In comparison to a control group, the average procedure time using FEops HEARTguide was reduced to 21 minutes from 55 minutes, and fluoroscopy time was cut to four minutes from 17 minutes.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Furthermore, the average contrast utilised during the procedure was 20ml, significantly less than the 80ml used in the control group.
These results highlight the potential of FEops HEARTguide to optimise procedural outcomes.
FEops HEARTguide is currently available in the US for usage in LAAO with devices such as WATCHMAN and WATCHMAN FLX and the Amplatzer Amulet.
This tool is also offered for use in the EU, UK, Canada, and Australia for Transcatheter Aortic Valve Implantation (TAVI) and LAAO procedures.
It has so far been used in more than 8,000 patients across over 300 hospitals worldwide.
FEops co-founder and CEO Matthieu De Beule said: “This real-world evidence reinforces the value of our pioneering digital twin strategy to alter the course of heart disease.
“Together we continue to advance how physicians access therapy options for patients at risk of stroke due to atrial fibrillation. The results support us in our mission to continue to spearhead AI-enabled predictive solutions that help treat the right heart disease patients with the right technology at the right time.”